| Form | Liquid |
|---|
| Host Species | Human |
|---|
| Clonality | Monoclonal |
|---|
| Isotype | IgG1-lambda |
|---|
| Purity | >95% purity as determined by SDS-PAGE. |
|---|
| Purification | Protein A/G purified from cell culture supernatant. |
|---|
| Concentration | 1mg/ml |
|---|
| Endotoxin Level | Please contact the lab for this information. |
|---|
| Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
|---|
| Species Reactivity | Human |
|---|
| Target | C4.4A, Matrigel-induced gene C4 protein, GPI-anchored metastasis-associated protein C4.4A homolog, MIG-C4, LYPD3, Ly6/PLAUR domain-containing protein 3 |
|---|
| Storage Buffer | 0.01M PBS, pH 7.4. |
|---|
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
|---|
| Expression System | Mammalian Cells |
|---|
| Accession Number | O95274 |
|---|
| Background | Lupartumab (BAY 1112623) is an anti-LYPD3 (C4.4A) monoclonal antibody that can be used for the synthesis of antibody-drug conjugate BAY 1129980.<br>• LY6/PLAUR domain containing 3 (LYPD3) maintains melanoma cell stemness and mediates an immunosuppressive microenvironment., PMID:37924160<br/>• m6A-dependent mature miR-151-5p accelerates the malignant process of HNSCC by targeting LYPD3., PMID:39009906<br/>• LY6/PLAUR domain containing 3 has a role in the maintenance of colorectal cancer stem-like cells., PMID:28238780<br/>• CircCBFB-mediated miR-28-5p facilitates abdominal aortic aneurysm via LYPD3 and GRIA4., PMID:32151690<br/> |
|---|
| Alternative Names | BAY1112623, BAY1129980, 1640971-88-5 |
|---|
| Note | For research use only. Not suitable for clinical or therapeutic use. |
|---|